Floatz logo

Zandelisib

Mantle Cell Lymphoma (MCL)

MEI Pharma, Inc.Small moleculePhase 1Dormant
C
33/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
18/ 100
Competitive Position
81/ 100

Competitive context

173 Active assets in the Mantle Cell Lymphoma (MCL) cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Ruijin Hospital
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BBB
Bendamustine
Czech Lymphoma Study Group
Phase 2BBB
VINCRISTINE SULFATE
M.D. Anderson Cancer Center
Phase 2BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Zandelisib is also rated in:

follicular lymphomaDormant
CCC
Indicative ·
54 / 100
View asset →
marginal zone lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →